<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bonnefond A</submitter><funding>Medical Research Council</funding><pagination>e55921</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3566098</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(2)</volume><pubmed_abstract>Vascular endothelial growth factor (VEGF) is a key chemokine involved in tissue growth and organ repair processes, particularly angiogenesis. Elevated circulating VEGF levels are believed to play a role in type 2 diabetes (T2D) microvascular complications, especially diabetic retinopathy. Recently, a genome-wide association study identified two common single nucleotide polymorphisms (SNPs; rs6921438 and rs10738760) explaining nearly half of the variance in circulating VEGF levels. Considering the putative contribution of VEGF to T2D and its complications, we aimed to assess the effect of these VEGF-related SNPs on the risk of T2D, nephropathy and retinopathy, as well as on variation in related traits.SNPs were genotyped in several case-control studies: French and Danish T2D studies (N(case</pubmed_abstract><journal>PloS one</journal><pubmed_title>What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications?</pubmed_title><pmcid>PMC3566098</pmcid><funding_grant_id>G1002084</funding_grant_id><pubmed_authors>Ndiaye NC</pubmed_authors><pubmed_authors>Pedersen O</pubmed_authors><pubmed_authors>Nezhad MA</pubmed_authors><pubmed_authors>El-Sayed Moustafa JS</pubmed_authors><pubmed_authors>Hercberg S</pubmed_authors><pubmed_authors>Saulnier PJ</pubmed_authors><pubmed_authors>Hansen T</pubmed_authors><pubmed_authors>Bonnefond A</pubmed_authors><pubmed_authors>Stathopoulou MG</pubmed_authors><pubmed_authors>Balkau B</pubmed_authors><pubmed_authors>Lauritzen T</pubmed_authors><pubmed_authors>Grarup N</pubmed_authors><pubmed_authors>Roussel R</pubmed_authors><pubmed_authors>Visvikis-Siest S</pubmed_authors><pubmed_authors>Dechaume A</pubmed_authors><pubmed_authors>Froguel P</pubmed_authors><pubmed_authors>Lantieri O</pubmed_authors><pubmed_authors>Charpentier G</pubmed_authors><pubmed_authors>Hadjadj S</pubmed_authors><pubmed_authors>Marre M</pubmed_authors></additional><is_claimable>false</is_claimable><name>What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications?</name><description>Vascular endothelial growth factor (VEGF) is a key chemokine involved in tissue growth and organ repair processes, particularly angiogenesis. Elevated circulating VEGF levels are believed to play a role in type 2 diabetes (T2D) microvascular complications, especially diabetic retinopathy. Recently, a genome-wide association study identified two common single nucleotide polymorphisms (SNPs; rs6921438 and rs10738760) explaining nearly half of the variance in circulating VEGF levels. Considering the putative contribution of VEGF to T2D and its complications, we aimed to assess the effect of these VEGF-related SNPs on the risk of T2D, nephropathy and retinopathy, as well as on variation in related traits.SNPs were genotyped in several case-control studies: French and Danish T2D studies (N(case</description><dates><release>2013-01-01T00:00:00Z</release><publication>2013</publication><modification>2026-05-05T11:09:29.699Z</modification><creation>2026-04-07T21:38:52.356Z</creation></dates><accession>S-EPMC3566098</accession><cross_references><pubmed>23405237</pubmed><doi>10.1371/journal.pone.0055921</doi></cross_references></HashMap>